• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ACIU

    AC Immune SA

    Subscribe to $ACIU
    $ACIU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

    IPO Year: 2016

    Exchange: NASDAQ

    Website: acimmune.com

    Peers

    $IMRA
    $NEXI

    Recent Analyst Ratings for AC Immune SA

    DatePrice TargetRatingAnalyst
    5/31/2024$8.00Buy
    BTIG Research
    12/20/2021$17.00 → $15.00Outperform
    SVB Leerink
    See more ratings

    AC Immune SA SEC Filings

    See more
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      4/30/25 7:15:09 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      3/13/25 7:32:22 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by AC Immune SA

      20-F - AC Immune SA (0001651625) (Filer)

      3/13/25 7:30:34 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      12/18/24 5:16:34 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      12/10/24 8:23:56 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      11/14/24 7:00:03 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      11/5/24 7:15:37 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      9/19/24 4:30:34 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      9/17/24 7:02:19 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      8/28/24 9:04:15 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AC Immune SA Leadership Updates

    Live Leadership Updates

    See more
    • AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

      AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Off

      12/1/23 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune SA Appoints New Chief Medical Officer

      AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will join the Company on October 1st, as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, currently Chief Medical Officer, will leave at the end of September to pursue a new role. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "It is with great pleasure that we welcome Dr Mendonça to our

      7/26/23 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

      Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. M

      10/29/21 6:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer

      Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain

      5/17/21 1:30:00 AM ET
      $VRTX
      $IRWD
      $GBIO
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors

      Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investments for several clinical-stage companies as a Partner at Sofinnova Investments LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Alan Colowick, MD, MPH, a deeply experienced biotech and investment executive, was elected to the Company’s Board of Directors at an extraordinary shareholders’ meeting today. Dr Colowick has more than 20 years of industry experience in both large and emerging biotech companies, serving in a broad a

      3/31/21 4:30:00 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AC Immune SA Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

      AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to date Lausanne, Switzerland, April 2, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced

      4/2/25 6:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

      AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine

      3/25/25 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune to Participate in Upcoming Investor Conferences

      AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Conference,Management will participate in investor meetings on March 11, 2025 Please contact your Leerink or Barclays representative or AC Immune to request a one-on-one meeting with AC Immune's manag

      3/4/25 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

      AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome Lausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim safety and tolerability data from the ABATE Phase 1b/2 tria

      12/10/24 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

      AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date Lausanne, Switzerland, November 14, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and immunogenicity data from the Phase

      11/14/24 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune to Present at the Jefferies 2024 London Healthcare Conference

      AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024. The fireside chat will take place on November 20, 2024, at 6:00 AM (ET) / 11:00 AM (GMT). A webcast of the fireside chat will be available on the Events Page of AC Immune's website. A replay will be archived in the same locatio

      11/13/24 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease

      AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in SeptemberPotentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic ADFDA Fast Track designation granted in July for ACI-35.030 (now "JNJ-2056") for AD Lausanne, Switzerland, September 17, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment

      9/17/24 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

      AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer's disease by AC Immune's partner, LMIThis Fast Track designation applies across Alzheimer's disease, progressive supranuclear palsy, and corticobasal degenerationFollows two previous Fast Track designations for ACI-35.030 and ACI-24.060 active immunotherapiesAffirms AC Immune's leadership and commitment to bringing precision medicine to the management of neurodegenerative diseases   Lausanne, Switzerland, August 28, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics

      8/28/24 9:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

      AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS morADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation compared to the antibody or small molecule alone Lausanne, Switzerland, July 31, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today u

      7/31/24 8:30:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease

      AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently init

      7/25/24 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AC Immune SA Financials

    Live finance-specific insights

    See more
    • AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

      AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)

      5/13/24 6:00:00 AM ET
      $ACIU
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

      AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further develop its SAIT and monoclonal antibody for cardiovascular disease and for Huntington's disease, respectively VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS

      7/27/21 8:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

      All-stock transaction maintains AC Immune's strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune's therapeutic development in Parkinson's disease AC Immune to immediately launch clinical development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson's disease Conference call scheduled today at 8:30 am ET / 2:30 pm CET LAUSANNE, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it is acquiring Affiris' portfoli

      7/27/21 7:30:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AC Immune SA Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on AC Immune with a new price target

      BTIG Research initiated coverage of AC Immune with a rating of Buy and set a new price target of $8.00

      5/31/24 7:33:11 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on AC Immune with a new price target

      SVB Leerink reiterated coverage of AC Immune with a rating of Outperform and set a new price target of $15.00 from $17.00 previously

      12/20/21 4:45:45 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on AC Immune with a new price target

      HC Wainwright & Co. reiterated coverage of AC Immune with a rating of Buy and set a new price target of $16.00 from $11.00 previously

      3/24/21 6:35:50 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AC Immune SA Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AC Immune SA

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      12/13/24 5:15:16 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AC Immune SA

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      11/14/24 4:36:20 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/9/24 4:30:11 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      12/19/23 4:53:10 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/14/23 5:15:22 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/10/23 4:01:15 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      1/27/23 4:41:51 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/14/22 1:41:00 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/14/22 1:37:48 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by AC Immune SA

      SC 13G - AC Immune SA (0001651625) (Subject)

      8/5/21 5:15:55 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care